CA11

Summary

CA11 (carbonic anhydrase 11 (inactive), HGNC:1370) is a protein-coding gene on chromosome 19q13.33, encoding Carbonic anhydrase-related protein 11 (O75493). Does not have a catalytic activity.

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA XI is likely a secreted protein, however, radical changes at active site residues completely conserved in CA isozymes with catalytic activity, make it unlikely that it has carbonic anhydrase activity. It shares properties in common with two other acatalytic CA isoforms, CA VIII and CA X. CA XI is most abundantly expressed in brain, and may play a general role in the central nervous system.

Source: NCBI Gene 770 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 44 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001217

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1370
Approved symbol	CA11
Name	carbonic anhydrase 11 (inactive)
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	CARP2, CARPX1
Ensembl gene	ENSG00000063180
Ensembl biotype	protein_coding
OMIM	604644
Entrez	770

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 retained_intron

ENST00000084798, ENST00000594088, ENST00000596080, ENST00000599267, ENST00000901033, ENST00000901034, ENST00000901035, ENST00000901036, ENST00000901037

RefSeq mRNA: 1 — MANE Select: NM_001217 NM_001217

CCDS: CCDS12729

Canonical transcript exons

ENST00000084798 — 9 exons

Exon	Start	End
ENSE00000717855	48645403	48645477
ENSE00000717856	48644427	48644569
ENSE00000717858	48639788	48639883
ENSE00000717860	48639549	48639621
ENSE00000717863	48639305	48639459
ENSE00000862932	48640095	48640280
ENSE00000862933	48638888	48639053
ENSE00001240406	48645566	48646187
ENSE00003138688	48637946	48638144

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 99.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.0105 / max 1248.7644, expressed in 1225 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181905	3.6204	438
181908	2.0004	418
181896	1.5171	462
181910	1.3317	500
181909	1.3024	450
181902	0.5326	169
181901	0.2710	120
181895	0.1952	95
181904	0.0871	44
181903	0.0795	37

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	99.74	gold quality
cerebellar hemisphere	UBERON:0002245	99.70	gold quality
cerebellar cortex	UBERON:0002129	99.69	gold quality
right frontal lobe	UBERON:0002810	99.61	gold quality
cerebellum	UBERON:0002037	99.47	gold quality
amygdala	UBERON:0001876	99.28	gold quality
nucleus accumbens	UBERON:0001882	99.28	gold quality
caudate nucleus	UBERON:0001873	99.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.18	gold quality
prefrontal cortex	UBERON:0000451	99.17	gold quality
cingulate cortex	UBERON:0003027	99.16	gold quality
anterior cingulate cortex	UBERON:0009835	99.14	gold quality
putamen	UBERON:0001874	99.12	gold quality
frontal cortex	UBERON:0001870	98.64	gold quality
Brodmann (1909) area 10	UBERON:0013541	98.34	gold quality
temporal lobe	UBERON:0001871	98.10	gold quality
cerebellar vermis	UBERON:0004720	98.02	gold quality
neocortex	UBERON:0001950	97.96	gold quality
frontal pole	UBERON:0002795	97.90	gold quality
telencephalon	UBERON:0001893	97.81	gold quality
cerebral cortex	UBERON:0000956	97.56	gold quality
forebrain	UBERON:0001890	97.37	gold quality
Ammon’s horn	UBERON:0001954	97.34	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.30	gold quality
brain	UBERON:0000955	97.22	gold quality
parietal lobe	UBERON:0001872	97.19	gold quality
central nervous system	UBERON:0001017	97.17	gold quality
lateral globus pallidus	UBERON:0002476	97.13	gold quality
paraflocculus	UBERON:0005351	97.13	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

9 targeting CA11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-26B-3P	98.71	67.49	1102
HSA-MIR-633	98.35	69.45	1167
HSA-MIR-6826-3P	98.19	66.32	1153

Literature-anchored findings (GeneRIF, showing 2)

• The CARP VIII and XI proteins were associated to non-hypoxic conditions and CARP XI also to the expression of cytoplasmic CA II staining suggesting that the CARPs play a role in tumorigenesis of diffusively infiltrating gliomas (PMID:29792187)
• results suggest that CA11 and CA10 negatively regulate neuronal activity-dependent glioma growth and inhibit glioma aggression. Thus, CA11/CA10 may represent a potential therapeutic target for the treatment of gliomas. (PMID:30636076)

Cross-species orthologs

18 orthologs

Organism	Symbol	Gene ID
danio_rerio	cahz	ENSDARG00000011166
danio_rerio	ca2	ENSDARG00000014488
mus_musculus	Car11	ENSMUSG00000003273
rattus_norvegicus	Car11	ENSRNOG00000021017
drosophila_melanogaster	CAH13	FBGN0033542
drosophila_melanogaster	CAH14	FBGN0034554
drosophila_melanogaster	CAH15	FBGN0034560
drosophila_melanogaster	CAH7	FBGN0037788
drosophila_melanogaster	CAH8	FBGN0038956
drosophila_melanogaster	CAH4	FBGN0039235
drosophila_melanogaster	CAH9	FBGN0039486
drosophila_melanogaster	CAH6	FBGN0039838
drosophila_melanogaster	CAH16	FBGN0040628
drosophila_melanogaster	CAH5	FBGN0040629
drosophila_melanogaster	CARPB	FBGN0052698
caenorhabditis_elegans		WBGENE00000279
caenorhabditis_elegans		WBGENE00000283
caenorhabditis_elegans	cah-6	WBGENE00000284

Paralogs (14): CA12 (ENSG00000074410), CA2 (ENSG00000104267), CA9 (ENSG00000107159), CA14 (ENSG00000118298), CA6 (ENSG00000131686), CA1 (ENSG00000133742), CA10 (ENSG00000154975), CA3 (ENSG00000164879), CA4 (ENSG00000167434), CA7 (ENSG00000168748), CA5B (ENSG00000169239), CA5A (ENSG00000174990), CA8 (ENSG00000178538), CA13 (ENSG00000185015)

Protein

Protein identifiers

Carbonic anhydrase-related protein 11 — O75493 (reviewed: O75493)

Alternative names: CA-RP XI, Carbonic anhydrase-related protein 2

All UniProt accessions (2): O75493, M0QXK8

UniProt curated annotations — full annotation on UniProt →

Function. Does not have a catalytic activity.

Subcellular location. Secreted.

Tissue specificity. Expressed abundantly in the brain with moderate expression also present in spinal cord and thyroid.

Similarity. Belongs to the alpha-carbonic anhydrase family.

RefSeq proteins (1): NP_001208* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001148	CA_dom	Domain
IPR023561	Carbonic_anhydrase_a-class	Family
IPR036398	CA_dom_sf	Homologous_superfamily
IPR041878	Alpha_CARP_X/XI	Family

Pfam: PF00194

UniProt features (11 total): sequence conflict 3, glycosylation site 3, signal peptide 1, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75493-F1	88.39	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 118, 170, 260

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 119 (showing top): RRAGTTGT_UNKNOWN, WANG_CLIM2_TARGETS_UP, TGCGCANK_UNKNOWN, GOMF_CARBONATE_DEHYDRATASE_ACTIVITY, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, AACWWCAANK_UNKNOWN, MODULE_66, FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP, WTGAAAT_UNKNOWN, GNF2_TM4SF2, P300_01, MODULE_295, GOMF_HYDRO_LYASE_ACTIVITY, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS

GO Biological Process (0):

GO Molecular Function (3): zinc ion binding (GO:0008270), hydro-lyase activity (GO:0016836), carbonate dehydratase activity (GO:0004089)

GO Cellular Component (2): extracellular region (GO:0005576), basolateral plasma membrane (GO:0016323)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transition metal ion binding	1
carbon-oxygen lyase activity	1
hydro-lyase activity	1
cellular anatomical structure	1
basal plasma membrane	1
plasma membrane region	1

Protein interactions and networks

STRING

1124 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CA11	ITPR1	Q14643	453
CA11	EVPLL	A8MZ36	451
CA11	SLFNL1	Q499Z3	449
CA11	BSG	P35613	409
CA11	GGTLC1	Q9BX51	356
CA11	REM2	Q8IYK8	348
CA11	REM1	O75628	347
CA11	ABHD1	Q96SE0	343
CA11	SLC4A2	P04920	316
CA11	ATXN3L	Q9H3M9	316
CA11	MCAM	P43121	296
CA11	ATXN3	P54252	295
CA11	CCAR1	Q8IX12	295
CA11	NMRK1	Q9NWW6	292
CA11	CA12	O43570	287
CA11	CA14	Q9ULX7	287

IntAct

9 interactions, top by confidence:

A	B	Type	Score
ANTXR1	POTEF	psi-mi:“MI:0914”(association)	0.530
TAZ	MANBA	psi-mi:“MI:0914”(association)	0.350
INSL5	LAMA5	psi-mi:“MI:0914”(association)	0.350
CRP	QSOX1	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CA11	HSPA5	psi-mi:“MI:0914”(association)	0.350
LCOR	CA11	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (16): CA11 (Affinity Capture-MS), BIRC6 (Affinity Capture-MS), PM20D2 (Affinity Capture-MS), CA11 (Affinity Capture-MS), CA11 (Affinity Capture-MS), CA11 (Affinity Capture-MS), CA11 (Affinity Capture-MS), CA11 (Affinity Capture-MS), CA11 (Synthetic Lethality), CA11 (Affinity Capture-RNA), CA11 (Affinity Capture-MS), BIRC6 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), CA11 (Negative Genetic), CA11 (Negative Genetic)

ESM2 similar proteins: A0JN41, A2VE04, F4HUC4, F4IHR4, F4JIK2, O04846, O43570, O70354, O75493, P08060, P09172, P0DO50, P15101, P18761, P18915, P22748, P23280, P28651, P35219, P48283, P48284, P61215, Q05754, Q10462, Q18932, Q5PPN4, Q5R4U0, Q5R665, Q5TZ24, Q64237, Q64444, Q68CI2, Q6UVY6, Q6ZNA5, Q75N35, Q7TT41, Q865C0, Q866X6, Q866X7, Q8CI85

Diamond homologs: A0A7H0DN92, A0JN41, B8V7P3, O43570, O57211, O70354, O75493, P00915, P00916, P00918, P00919, P00920, P00921, P00922, P04195, P07450, P07451, P07630, P0DSY1, P0DSY2, P14141, P16015, P20508, P23589, P27139, P28651, P35217, P35218, P35219, P43165, P43166, P48282, P61215, P83299, Q18932, Q1LZA1, Q5PPN4, Q5R4U0, Q5R665, Q5S1S4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1691 predictions. Top by Δscore:

Variant	Effect	Δscore
19:48639049:TGCAT:T	acceptor_gain	1.0000
19:48639050:GCAT:G	acceptor_gain	1.0000
19:48639051:CATC:C	acceptor_gain	1.0000
19:48639054:C:CC	acceptor_gain	1.0000
19:48639055:T:A	acceptor_loss	1.0000
19:48639059:G:GC	acceptor_gain	1.0000
19:48639456:TCAT:T	acceptor_gain	1.0000
19:48639457:CAT:C	acceptor_gain	1.0000
19:48639457:CATC:C	acceptor_gain	1.0000
19:48639459:TC:T	acceptor_loss	1.0000
19:48639460:C:CC	acceptor_gain	1.0000
19:48639547:A:AC	donor_gain	1.0000
19:48639548:C:CT	donor_gain	1.0000
19:48639548:CT:C	donor_gain	1.0000
19:48639753:A:C	donor_gain	1.0000
19:48639759:C:CA	donor_gain	1.0000
19:48639762:T:TA	donor_gain	1.0000
19:48639786:A:AC	donor_gain	1.0000
19:48639787:C:CC	donor_gain	1.0000
19:48640090:ACTAC:A	donor_loss	1.0000
19:48640092:TA:T	donor_loss	1.0000
19:48640094:C:A	donor_gain	1.0000
19:48640094:C:G	donor_loss	1.0000
19:48640276:CGGAG:C	acceptor_gain	1.0000
19:48640280:GCTGT:G	acceptor_loss	1.0000
19:48640281:C:CC	acceptor_gain	1.0000
19:48640282:T:G	acceptor_loss	1.0000
19:48645336:AGGTT:A	donor_gain	1.0000
19:48645340:T:TA	donor_gain	1.0000
19:48638141:TCCA:T	acceptor_gain	0.9900

AlphaMissense

2120 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:48639362:G:C	C246W	0.999
19:48640260:G:C	N102K	0.999
19:48640260:G:T	N102K	0.999
19:48644505:G:C	S69R	0.999
19:48644505:G:T	S69R	0.999
19:48644507:T:G	S69R	0.999
19:48644526:A:C	C62W	0.999
19:48644527:C:G	C62S	0.999
19:48644527:C:T	C62Y	0.999
19:48644528:A:T	C62S	0.999
19:48644556:C:A	W52C	0.999
19:48644556:C:G	W52C	0.999
19:48639043:A:G	L269P	0.998
19:48639357:T:A	E248V	0.998
19:48639363:C:G	C246S	0.998
19:48639363:C:T	C246Y	0.998
19:48639364:A:G	C246R	0.998
19:48639364:A:T	C246S	0.998
19:48639385:C:A	G239C	0.998
19:48639385:C:G	G239R	0.998
19:48640246:A:T	V107D	0.998
19:48644503:G:T	P70H	0.998
19:48644528:A:G	C62R	0.998
19:48644535:C:A	W59C	0.998
19:48644535:C:G	W59C	0.998
19:48644537:A:G	W59R	0.998
19:48644537:A:T	W59R	0.998
19:48644558:A:G	W52R	0.998
19:48644558:A:T	W52R	0.998
19:48638959:C:A	R297M	0.997

dbSNP variants (sampled 300 via entrez): RS1000296980 (19:48644083 G>T), RS1000364775 (19:48641437 T>A), RS1000649208 (19:48643649 T>A,C,G), RS1001041792 (19:48646156 T>C), RS1001059334 (19:48646448 AG>A,AGG), RS1001542678 (19:48642929 A>G,T), RS1001777111 (19:48644785 G>A,T), RS1002174230 (19:48637741 T>A,C,G), RS1002273151 (19:48641198 T>G), RS1002326164 (19:48645010 CT>C,CTT), RS1002653821 (19:48646581 C>A,G,T), RS1003456931 (19:48647663 A>G,T), RS1003526314 (19:48638652 C>T), RS1003796977 (19:48641558 G>A), RS1003986851 (19:48639090 A>C,G,T)

Disease associations

OMIM: gene MIM:604644 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2420 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 28,768 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL20	ACETAZOLAMIDE	4	28,768

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

14 potent at pChembl≥5 of 14 total, top 14 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.92	Ki	1.2	nM	CHEMBL4080604
8.39	Ki	4.1	nM	CHEMBL4097126
8.35	Ki	4.5	nM	CHEMBL4081547
8.24	Ki	5.7	nM	CHEMBL4070963
8.24	Ki	5.8	nM	CHEMBL4061260
8.24	Ki	5.7	nM	ACETAZOLAMIDE
8.23	Ki	5.9	nM	CHEMBL4069928
8.22	Ki	6	nM	CHEMBL4099555
8.21	Ki	6.1	nM	CHEMBL4089415
8.20	Ki	6.3	nM	CHEMBL4064015
8.16	Ki	6.9	nM	CHEMBL4091812
7.34	Ki	45.5	nM	CHEMBL4104834
7.08	Ki	82.3	nM	CHEMBL4093328
7.06	Ki	87.3	nM	CHEMBL4072614

PubChem BioAssay actives

14 with measured affinity, of 23 total; 14 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
sodium 2-hydroxy-3-[(4-sulfamoylphenyl)carbamothioyldiazenyl]-1H-indole-5-sulfonate	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0012	uM
1-[(2-hydroxy-5-nitro-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0041	uM
1-[(5-fluoro-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0045	uM
1-[(2-hydroxy-5-methyl-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0057	uM
Acetazolamide	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0057	uM
1-[(5-chloro-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0058	uM
1-[(2-hydroxy-5-iodo-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0059	uM
1-[[2-hydroxy-5-(trifluoromethoxy)-1H-indol-3-yl]imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0060	uM
1-[(5-bromo-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0061	uM
1-[(5,7-dibromo-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0063	uM
1-[(2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0069	uM
1-[(7-fluoro-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0455	uM
1-[(5,7-dichloro-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0823	uM
1-[(7-chloro-2-hydroxy-1H-indol-3-yl)imino]-3-(4-sulfamoylphenyl)thiourea	1454029: Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	ki	0.0873	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	7
Estradiol	decreases expression, increases expression, affects cotreatment	3
bisphenol A	decreases methylation, increases expression	2
aristolochic acid I	increases expression	1
afuresertib	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
terbufos	decreases methylation	1
trichostatin A	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sodium arsenite	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	increases expression	1
(+)-JQ1 compound	decreases expression	1
Fulvestrant	decreases methylation	1
Air Pollutants	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Fonofos	decreases methylation	1
Oxygen	increases expression	1
Parathion	decreases methylation	1
Silicon Dioxide	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1
Tretinoin	decreases expression	1
Triclosan	increases expression	1
Okadaic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4036367	Binding	Inhibition of recombinant human membrane bound carbonic anhydrase 11 expressed in Escherichia coli pretreated for 15 mins prior to testing by stopped-flow assay	Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.